Trial Profile

A Phase 2 Study of Apalutamide in Active Surveillance Patients

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apalutamide (Primary)
Indications Adenocarcinoma; Carcinoma; Prostate cancer
Focus Therapeutic Use

Most Recent Events

10 Jan 2023 Results assessing active surveillance is a safe and effective strategy for men with lower-risk prostate cancer who want to avoid local therapy published in the Journal of Urology
19 Feb 2022 Results of an analysis assessing the transcriptional profiling of tumor tissue obtained from men presented at the 2022 Genitourinary Cancers Symposium
28 Dec 2021 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Terminated due to slow accrual

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com